期刊
EUROPEAN HEART JOURNAL
卷 42, 期 2, 页码 -出版社
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehaa736
关键词
Cardiorenal; Chronic kidney disease; Finerenone; Mineralocorticoids; Mineralocorticoid receptor antagonists
资金
- Bayer AG, the manufacturer of finerenone
- Bayer AG
This review covers the development of mineralocorticoid receptor antagonists (MRAs) over the last 80 years, discussing the differences in mechanisms and effects between nonsteroidal and steroidal MRAs. Nonsteroidal MRAs demonstrate important distinctions in distribution, binding mode, and gene expression compared to steroidal MRAs.
This review covers the last 80 years of remarkable progress in the development of mineralocorticoid receptor (MR) antagonists (MRAs) from synthesis of the first mineralocorticoid to trials of nonsteroidal MRAs. The MR is a nuclear receptor expressed in many tissues/cell types including the kidney, heart, immune cells, and fibroblasts. The MR directly affects target gene expression-primarily fluid, electrolyte and haemodynamic homeostasis, and also, but less appreciated, tissue remodelling. PathophysioLogical overactivation of the MR Leads to inflammation and fibrosis in cardiorenal disease. We discuss the mechanisms of action of nonsteroidal MRAs and how they differ from steroidal MRAs. Nonsteroidal MRAs have demonstrated important differences in their distribution, binding mode to the MR and subsequent gene expression. For example, the novel nonsteroidal MRA finerenone has a balanced distribution between the heart and kidney compared with spironolactone, which is preferentially concentrated in the kidneys. Compared with eplerenone, equinatriuretic doses of finerenone show more potent anti-inflammatory and anti-fibrotic effects on the kidney in rodent models. Overall, nonsteroidal MRAs appear to demonstrate a better benefit-risk ratio than steroidal MRAs, where risk is measured as the propensity for hyperkahemia. Among patients with Type 2 diabetes, several Phase II studies of finerenone show promising results, supporting benefits on the heart and kidneys. Furthermore, finerenone significantly reduced the combined primary endpoint (chronic kidney disease progression, kidney failure, or kidney death) vs. placebo when added to the standard of care in a large Phase III trial.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据